We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Information on depleted uranium (DU) including what it is, its uses, health effects and protection from exposure.
Submission dates and how the submissions using the EC decision reliance procedure work.
This national report provides insights into the care experienced by cancer patients across England who were treated as day cases or inpatients during the first three months of 2010.
A statement from the Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment (COC).
Estimated proportion of all malignant cancers where patients first presented as an emergency.
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
This document explains the Prostate Cancer Risk Management Programme (PCRMP), PSA testing and evidence against a national screening programme.
Information on the risks from low levels of ionising radiation.
How to apply for a clinical trial including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Guidance to help health professionals, social care staff and family members to help someone with learning disabilities to be screened for cancer.
One and 3- year unadjusted and case-mix adjusted ‘percentage of all cancers diagnosed at stages 1 and 2’ indicator nationally and at sub–Integrated Care Board (sub-ICB) level.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (6 March 2024) approved the medicine piflufolastat (18F) (Pylclari) as a diagnostic tool for people with suspected or known prostate cancer.
Game-changing AI technology will be rolled out to all radiography departments in England in a matter of weeks – backed by £15.5 million in new Government funding.
Information on the waiting times of patients with suspected cancer and those subsequently diagnosed with cancer. Information on the number of people who attended outpatient appointments within two weeks of an urgent referral by their GP for suspected cancer or...
High quality care is critical to improving cancer outcomes. While this country has many of the elements required to collect, analyse and publish information; there are also deficiencies in cancer intelligence.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).